Omico

11/04/2026

💙For many people and families, including those facing cancer, pets are more than companions. They bring comfort, routine, and moments of light when they’re needed most.

Across Omico, our team shares a love of animals (we even have a dedicated chat just for them!). From the furriest to the scaliest (yes, there’s “Gamera” the turtle!), they’re a big part of our lives too.

🐕🐈🐇Today, on , we’re celebrating the animals who sit beside us, walk with us, greet us at the door, and quietly support us in ways words often can’t.

Who’s your special family member to acknowledge today?

09/04/2026

People facing cancer often draw strength from those around them — family, clinicians, and community.

from BEAT Bladder Cancer Australia is one way people are coming together around those affected by cancer.

If you’d like to be part of it, details are below 👇

Save the Date 🌟
Anna’s Walk — Sunday 17 May 2026

Show your support for and join a free bladder cancer awareness walk taking place across Australia and New Zealand.

We’ll be walking in:
📍 Sydney
📍 Melbourne
📍 Brisbane
📍 Perth
📍 Adelaide
📍 Canberra
📍 Hobart
📍 Tamworth
📍 Wellington NZ

It’s less than three months away - mark your calendars now.

Bring your family, friends, and colleagues. Together, we can make a difference.

For further details go to: www.beatbladdercanceraustralia.org.au/annas-walk/

08/04/2026

Our team do amazing things.
Not because it’s easy. Because it matters.

1.0 didn’t just happen.
It took persistence, care, and a lot of work behind the scenes.

Last week, we stopped for a moment to say thank you to our Omico team.

And now … we’re already into PrOSPeCT 2.0.

Couldn’t have done this without our team. 🙌

www.omico.org.au

07/04/2026

✨On World Health Day, we’re sharing what drives our work.

For us, it’s not just new discoveries—it’s making sure those discoveries reach people.

Omico’s vision is to extend and enhance the lives of Australians with cancer through research-led and evidence-based precision oncology.

That means taking proven advances in science and putting them into the hands of clinicians and patients—expanding treatment options and informing what comes next.

Because progress only matters if it reaches the people who need it.

02/04/2026

Precision oncology is moving—and the evidence is building.
Each step helps more Australians access options.

Our March eNewsletter brings together new milestones, national activity, and globally relevant results from MoST published in JAMA Oncology.

🔗 Read the March 2026 issue: https://zcu.nz/iWsp?m=0
✉️ Subscribe to receive future editions: https://omico.org.au/webform/

Our next issue will be released in May.

31/03/2026

Following National Doctors’ Day, we acknowledge the 1,519 clinicians across Australia who have referred more than 35,000 patients to Omico.

Because of you, Australians facing cancer have had the opportunity to access, at no cost, comprehensive genomic profiling and treatment matching.
Precision oncology isn’t yet routine, funded care in Australia. Your referrals are what make access possible.

Thank you for backing your patients and their families with every option available.

31/03/2026

Precision oncology is often described in terms of new treatments.

But it is also about selecting the right treatment and avoiding those that are not the best match and may cause long-term harm.

At our 1.0 celebration, Beth Ivimey reflected:

“You, hopefully, will not be given drugs that do you harm. In my case, I did - I had the usual chemotherapy, immunotherapy and the consequences of immunotherapy - we know that they go on for ever and ever and ever - and that is actually my biggest problem. To save patients that is enormous.”

Comprehensive genomic profiling can help match patients to therapies most likely to benefit them—and reduce exposure to ineffective treatment and long-term toxicity.

Mainstreaming precision oncology means embedding that level of informed decision-making into routine cancer care.

27/03/2026

A new report from Rare Cancers Australia highlights how important clinical trials are for people with rare and challenging cancers—and what needs to change to improve access.

For many patients, clinical trials aren’t a last option. They can be an essential pathway to treatment.

At Omico, we see this every day. Through our programs, Australians with incurable and rare cancers are accessing genomic profiling and being matched to clinical trials and treatments based on biomarkers in their cancer.

As more trials focus on tumour-agnostic therapies—guided by biomarkers rather than cancer type—this genomic profiling becomes essential. Without it, patients may never be identified for trials that could help them.

Importantly, this report brings together insights from across the sector, including people with lived experience of cancer and cancer clinical trials.

There’s more to do—but together, we can improve access for more Australians who need it.

For people with rare cancers, who face poor survival outcomes and limited access to treatments, clinical trials are not a last resort - they can be the only viable treatment option.

Yet many people in our community face challenges in finding and taking part in clinical trials.

Through a national policy roundtable series across Melbourne, Sydney and Brisbane and online at the end of last year, we explored Australia’s strengths as a clinical trials destination and the critical opportunities to increase access to clinical trials for those who need them most.

In partnership with Cancer Trials Australia, we convened people with lived experience, clinicians, researchers, policymakers and industry representatives, to identify practical ways to:
🔹 increase the number of clinical trials for people with rare cancers in Australia
🔹 better connect clinicians and patients with the trials and information they need and support people with rare cancers to take part in trials, regardless of where they live
🔹 strengthen Health Technology Assessment pathways to improve subsidised access to medicines beyond the trial setting.

Read the key insights and actions from the Policy Roundtable Series at: https://bit.ly/4szi8lA

Thank you Cancer Trials Australia, who partnered with us on this series, as well as our sponsors, speakers and attendees who generously shared their time, ideas and commitment to maximising rare cancer clinical trials in Australia.

24/03/2026

Around 70-80% of the patients Dr Sara Wahlroos sees have incurable cancer, with a median overall survival of 12–14 months.

An Upper GI Medical Oncologist and Phase I trialist at Chris O'Brien Lifehouse, she reflected on what has meant in practice.

She shared:
“This (PrOSPeCT) provides what I refer to as an ace up my sleeve ... it provides hope ... and even if it doesn't prove actionable biomarkers, at least we know that we haven't missed something that could potentially provide a significant overall survival benefit for these patients.”

Under PrOSPeCT 1.0:
• 74.5% of adults received a matched treatment recommendation
• 12.1% have enrolled in a clinical trial so far
• 25.5% accessed therapy outside a trial so far

For around 1,200 clinicians across Australia, Omico’s PrOSPeCT has supported access to precision oncology to help guide treatment decisions for their patients.

20/03/2026

👏 More than $750,000 raised—and still growing.

An incredible effort from Rare Cancers Australia and everyone behind the Kosi Challenge.

Love your work—what a community.
Kosi, Kosi, Kosi – Oi, oi, oi! , indeed!

✨ THANK YOU ✨ for helping us make this year’s Kosi Challenge the biggest and best yet!

We’ve smashed our $750,000 fundraising target and the total is still climbing.

Our fundraising is currently sitting at a record-breaking total over $766,000 – with every dollar making a difference helping us support people affected by rare and less common cancers.

We are so grateful for all the time, effort, energy and support we’ve received in the lead-up to the Kosi Challenge.

Whether you’ve been a sponsor, donated to a friend, walked virtually or reached the summit of Mt Kosciuszko, you’ve played a vital role in making this weekend such a success, and giving strength and hope to the rare community.

Kosi, Kosi, Kosi – Oi, oi, oi!

19/03/2026

This week, The Australian has highlighted new findings from Omico’s program, bringing national attention to how genomic testing is helping to identify treatment options, often through clinical trials, for people with incurable, advanced or rare cancers.

These findings, recently published in JAMA Oncology and recognised internationally, show that precision oncology can improve outcomes for patients with difficult-to-treat cancers who are able to access matched therapies. While progress is being made, many Australians still face barriers to accessing these treatments.

At Omico, we’re working with clinicians, researchers and partners across the country to connect people with options and clinical trials—and to help make these approaches more accessible over time.

Want to know more?

🔗 Media coverage (The Australian, subscriber access): https://www.theaustralian.com.au/health/medical/patients-lives-lost-as-cancer-drugs-out-of-reach/news-story/d55181422a124add112e74d8e27d63b8
🔗 Read the research (JAMA Oncology): https://jamanetwork.com/journals/jamaoncology/fullarticle/2845808?resultClick=1
🔗 Editorial commentary (Vivek Subbiah): https://lnkd.in/gTRSk2F6

17/03/2026

Every 15 minutes, an Australian with incurable cancer is referred to .

At our recent event, Beth Ivimey shared what comprehensive genomic profiling meant for her.

Diagnosed with stage IV cholangiocarcinoma, she accessed matched therapy through clinical trials identified via genomic profiling. Beth has now outlived her original prognosis six-fold.

But what stayed with us was not just this number.

“A lot of people use the word hope. For me, I look forward to things. There's always moving forward.”

Precision oncology is not only about genomic reports — it’s about guiding treatment decisions.

More than 21,500 Australians have now been referred to PrOSPeCT, expanding access to matched treatment options that might otherwise be missed.